Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Withdrawn 4Completed 3Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Liver Neoplasms 3Stomach Neoplasms 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Solid Malignancies 1Seminoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Non Small Cell Lung Cancer NSCLC 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Metastatic Malignant Female Reproductive System Neoplasm 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Immunotherapy 1Hydronephrosis 1

Interventions

Gemcitabine 18pembrolizumab 16Cisplatin 16Nivolumab 15atezolizumab 11durvalumab 9Specimen Handling 9Magnetic Resonance Spectroscopy 9Cystectomy 8Carboplatin 7Ipilimumab 6Fluorouracil 6avelumab 5Mitomycin 5sacituzumab govitecan 4erdafitinib 4enfortumab vedotin 4Surgical Procedures, Operative 4Immunoglobulin G 4Disulfides 4Biopsy 4tremelimumab 3cabozantinib 3Transurethral Resection of Bladder 3Surveys and Questionnaires 3Radiation 3Platinum 3Paclitaxel 3Leucovorin 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Urinary Bladder Neoplasms × tremelimumab × Clear all
NCT04960709 2026-06-04

VOLGA

AstraZeneca

Phase 3 Active not recruiting
712 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03682068 2026-05-28

NILE

AstraZeneca

Phase 3 Active not recruiting
1,246 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03601455 2026-05-11

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
13 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡